Short Stature With Delayed Bone Age: GH Deficiency or Normal Variant?
An 8-year-old boy is referred for short stature. His height is 112 cm (SDS −2.6), weight 22 kg (BMI 17.5), and midparental height 172 cm (SDS −0.3). Over 18 months his growth velocity is 4.0 cm/year. Bone age is 6 years. Examination shows no dysmorphism, normal proportions, and prepubertal genitalia. He has no chronic gastrointestinal, renal, or cardiac symptoms; celiac screen and TSH are normal. IGF-1 is 120 ng/mL (mid-normal for age). The family asks whether he needs growth hormone and whether a brain tumor has been missed. They are worried because a cousin was treated with GH.
1. How do you interpret the auxology and bone age? What is your working diagnosis, and how likely is growth hormone deficiency?
Read the worked answer
The key data are height SDS −2.6, growth velocity 4.0 cm/year, bone age delayed by 2 years, midparental height SDS −0.3, and a normal IGF-1. This pattern is not specific for GH deficiency. A growth velocity of 4 cm/year is below the expected 5–6 cm/year for age and is more concerning than a single short height. However, bone age delay with a normal IGF-1 and no dysmorphism fits constitutional delay of growth and puberty or familial short stature better than severe GH deficiency. GH deficiency often shows disproportionate slowing of growth, a low IGF-1, and sometimes other pituitary hormone deficits; none are present. The normal midparental height argues against familial short stature as the sole explanation, so serial measurements are essential. I would not label this GH deficiency on the basis of one IGF-1 and a delayed bone age.
2. What diagnostic testing, if any, would you order next, and what are the limitations of GH stimulation tests and IGF-1 in this setting?
Read the worked answer
I would first confirm the growth pattern with accurate serial heights over 6–12 months and review the bone-age film for technique. Screening for chronic disease is already largely negative. I would check a repeat IGF-1 and IGFBP-3, and consider a GH stimulation test only if growth velocity remains poor or IGF-1 is low. Limitations matter: IGF-1 is age- and puberty-dependent and can be normal in partial GH deficiency; GH stimulation tests are poorly reproducible, influenced by nutrition and puberty, and can be abnormal in constitutional delay. A random GH is not useful. If GH deficiency is biochemically suggested, MRI of the pituitary/hypothalamus is indicated to look for structural causes. In this boy, the pretest probability of GH deficiency is low, so the main risk of immediate provocative testing is a false-positive result leading to unnecessary treatment.
3. How would you counsel the family about GH treatment, MRI, and monitoring?
Read the worked answer
I would explain that short stature is common and that his growth pattern is more consistent with a delay in maturation than with a brain tumor. I would not promise GH and would not start it without a clear diagnosis. The plan is to measure height every 3–6 months, monitor puberty, and repeat bone age in 12 months if growth remains slow. If growth velocity falls further or IGF-1 is low, we would proceed to GH stimulation and possibly MRI. If GH deficiency is confirmed, GH treatment can improve adult height, but benefits are modest in idiopathic short stature and require daily injections, monitoring of growth, thyroid function, glucose, and hip/knee symptoms. I would also address the family’s anxiety about the cousin: treatment in one child does not mean this child has the same diagnosis.